512 Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B
暂无分享,去创建一个
C. Yurdaydın | Y. Batur | H. Senturk | R. Hindes | M. Raptopoulou-Gigi | A. Boroń-Kaczmarska | H. Brett-Smith | Z. Goodmans | J. Vaughah